{"262": "Mother-to-child transmission", "276": "maternal viral load .29 000 copies/ml", "278": "more than 400,000", "316": "facilitating the migration of maternal HIV-1-infected cells across the placental barrier", "305": "", "306": "significantly decreased the level of total placental DC-SIGNR transcripts", "307": "HIV-1 would preferentially binds CCR5 on endothelial cells", "277": "15-45%", "312": "Genetic variants in CCR5 have been shown to influence vertical transmission of HIV-1", "318": "promotes pathogen elimination by opsonization and phagocytosis", "321": "The promoter variant reduced transcriptional activity in vitro", "568": "interferon-induced transmembrane", "569": "three", "570": "2BP", "571": "the interaction of IFITM5 with FKBP11", "572": "bone formation", "573": "S-palmitoylation", "574": "bonerestricted IFITM-like (BRIL) protein", "575": "because the region upstream of the ifitm5 gene lacks the interferon regulatory elements", "576": "68% and 66%", "577": "85%", "580": "aspartate", "917": "", "918": "single-stranded, linear, and nonsegmented RNA of around 31 kb", "919": "100%", "920": "", "921": "5", "1658": "human coronavirus", "1659": "HCoV-OC43", "1660": "HCoV\u2010HKU1", "1717": "Highly virulent species of HCoV", "1718": "14% to 45%", "1719": "HCoV-OC43 and HCoV-229E", "1720": "HCoV-HKU1, HCoV-OC43, HCoV-NL63, and HCoV-229E", "1612": "Intranasal entry", "1615": "highly vascularized", "1616": "Metered dose inhalers (MDIs) and dry powder inhalers (DPIs)", "1617": "naked siRNAs", "1618": "Intranasal entry", "1619": "respiratory bronchioles, alveolar ducts, and alveolar sacs", "1620": "between 1-5 \u03bcm", "1621": "non-toxic delivery vectors. An important point for siRNA-mediated inhibition of gene expression is whether the observed effects are specific rather than due to off-target effects and free from potential interferon responses", "1622": "", "1623": "10", "1624": "Chinese IBV", "257": "7.3 billion", "248": "Middle East respiratory syndrome coronavirus", "249": "Transmissibility and severity", "250": "January 30, 2020", "251": "H7N9", "252": "modeling articles", "253": "20% to 30%", "254": "20%", "255": "", "1657": "35\u202f000 to 60\u202f000", "550": "HMPV", "553": "no approved vaccines or medications available for most of the respiratory viruses", "544": "Gammaproteobacteria", "545": "multidrug-resistant bacteria", "327": "influenza and respiratory syncytial viruses", "465": "facilitate pathogen clearance", "467": "Dysregulation of the antibody response can lead to an autoimmune disease, malignancy, or enhanced infection", "474": "hybridoma", "476": "somatic rearrangement", "478": "new diagnostic, therapeutic, and research reagents", "485": "developmental pathway", "489": "stabilized versions of the fusion (F) protein in the pre-fusion conformation have led to insights in the B cell's response to infection and has generated potentially safer and more efficacious vaccine candidates", "490": "identification of B cells that target this relatively conserved site", "494": "protection against infection", "497": "The study of autoantigen-specific B cells and a detailed analysis of B cell subsets with pathogenic potential in humans could lead to a better understanding", "557": "2012", "558": "21%", "559": "males more than females", "560": "Dromedary camels", "562": "11-13 days", "563": "16 days", "564": "no specific treatment", "565": "aged 40 and above", "1631": "", "1632": "1104 nucleotide sequence with a poly-A tail containing an ORF of 783 bp", "1633": "increasing IL-6 gene and protein expression", "1634": "promotes germinal center formation, immunoglobulin (Ig) isotype switching, somatic hypermutation to enhance antigen affinity, and lastly, the formation of long-lived plasma cells and memory B cells", "567": "differences from the average codon usage frequencies in the host genome", "566": "mutational pressure and translational selection", "328": "", "329": "", "330": "NK cells", "331": "reactive oxygen species", "332": "reactive oxygen species", "1592": "", "1593": "an accountable global body will always be needed to promote, set standards in, and evaluate progress toward better health for people in all countries", "1595": "lowincome or middle-income country", "1596": "open-minded and creative", "502": "", "504": "Improved access to health care, better nutrition and improved living conditions", "507": "900,000", "510": "", "511": "42% decrease in pneumonia-specific mortality", "512": "42%", "513": "1.8 times", "514": "81%", "515": "", "516": "lead to significant morbidity", "517": "Indoor air pollution from use of solid or biomass fuels", "518": "point-of-care lung ultrasound", "519": "a dense or fluffy opacity that occupies a portion or whole of a lobe, or the entire lung", "520": "pneumococcal conjugate vaccination", "521": "18%", "522": "", "524": "", "530": "pneumococcal conjugate vaccination-7 introduction", "532": "", "533": "ambulatory pneumonia", "534": "measles", "535": "antibody levels drop sharply after birth", "536": "substantial decrease in the incidence", "537": "host and environmental", "538": "increases odds of pneumonia by 1.6 times", "539": "HIV infection", "540": "", "541": "Influenza vaccination during pregnancy is safe, provides reasonable maternal protection against influenza, and also protects infants for a limited period from confirmed influenza infection", "923": "a rare complication of pneumonia", "1625": "an enveloped, positive-stranded RNA virus that preferentially replicates in hepatocytes", "1626": "At least 170 million people worldwide", "1627": "progression to cirrhosis and hepatocellular carcinoma", "1628": "pegylated alpha-interferon and ribavirin", "2129": "Calf septicemia", "2131": "human urine", "2130": "Mybiosource", "2132": "the liver", "2133": "", "2134": "Fe", "2135": "it limits the amount of Fe that can be utilized by pathogens", "2136": "nutritional source", "2137": "control of excessive Fe absorption", "2138": "reduces Fe release and enteric Fe absorption", "2139": "reactive oxygen species", "2140": "superoxide dismutase [21] , TAS", "1635": "expression of adjacent genes", "593": "FOCRT", "595": "infected lambs", "581": "a rare, sudden onset of unilateral chorioretinopathy", "582": "granularity appearance of the macula", "583": "herpes simplex virus (HSV) I-II, varicella zoster virus", "584": "Multimodal Imaging", "1597": "Parainfluenza virus 4, respiratory syncytial virus B and enterovirus", "1598": "Coronavirus OC43", "1599": "2-5 times higher", "1600": "continent of Africa", "1601": "human-animal interfaces", "1602": "death", "1603": "Coronavirus OC43", "1604": "13.3%", "1605": "12.5%", "1606": "increased severity of illness in the clinical sample", "1607": "active community surveillance", "1608": "their world-wide occurrence, ease of transmission and considerable morbidity and mortality effecting people of all ages", "1609": "two to three times", "1610": "acute RTIs", "1611": "acute respiratory infections", "1613": "winter and early spring months", "1614": "RSV and rhinovirus", "1629": "acute RTIs", "1630": "13%", "2125": "544 base pairs", "2126": "deletions or insertions", "2127": "high level of homology", "2128": "adult riding, racing and show horses", "2167": "acellular", "2168": "Southeast Asia", "2169": "whole cell", "2170": "sore throat, nasal congestion, or myalgia", "2171": "nasal", "2173": "every 2 to 4 years", "2174": "minimum of 2 weeks of cough, whoop, or posttussive vomiting", "2175": "laboratory tests that are positive for influenza", "2176": "diagnosis will often not alter patient management", "2177": "influenza, respiratory syncytial virus (RSV), para-influenza virus (PIV), and adenovirus", "585": "urbanization spatially combines risk factors to produce particular types of peri-urban landscapes with significantly higher HPAI H5N1 emergence risk", "586": "", "587": "", "588": "emergence events are precipitated by the intensifying of biological, environmental, ecological, and socioeconomic drivers", "590": "stochastic gradient boosting", "591": "better predictive power at the national level than at the delta level", "592": "strong association", "589": "high land-use diversity landscapes", "594": "Intensive systems allow for virus evolution", "596": "the percentage of land under rice in peri-urban areas and rural areas is similar", "597": "Intensive systems allow for virus evolution", "598": "increases the risk of outbreaks", "599": "the poultry population fell 15%", "600": "", "655": "", "651": "", "658": "weak base and immunomodulator", "661": "inhibiting virus entry", "662": "", "924": "a family of AAA-ATPase proteins", "926": "SPG4, KATNB1", "927": "missense mutation in Katnal1", "928": "KATNAL2", "929": "Katanin p60 subunit A-like 1", "930": "central nervous system", "931": "working memory and spatial memory", "932": "neuronal morphology", "1220": "in the presence of 2% DMSO in parallel", "1222": "calcium", "1223": "transmembrane domain 3", "1224": "voltage-gated Ca(2+) channel (VGCC) inhibitor", "1225": "over 70", "1226": "11-kb", "1227": "vi.01055-17", "1228": "capsid (C), membrane (premembrane [prM] and membrane [M] ), and envelope (E)", "1229": "participate in viral replication, virion assembly, and virus escape from immune surveillance", "1230": "Recombinant viral particles", "1231": "high-throughput screening", "1232": ">10", "1233": "luciferase-reporting replicon enveloped by the JEV structural proteins", "1234": "selective index of >10", "430": "nine", "431": "double-stranded", "432": "VP1-VP4, VP6 and VP7", "433": "NSP1-NSP5/NSP6", "434": "qualitative real-time polymerase chain reaction", "634": "early identification of outbreak, (2) rapid expansion of patients, (3) high risk of nosocomial transmission, (4) unpredictability of size impacted, and (5) lack of backup resource", "642": "", "644": "building a temporary new IDH or reconstructing an existing hospital", "645": "highly contagious with multiple transmission route, high exposure dose, long daily contact hours, and ICU stay", "669": "", "1935": "Recombinant viruses", "1936": "anterograde", "1937": "method of delivery of the G gene", "1938": "Recombinant viruses", "2141": "a high molecular weight sulfated polymer derived from red seaweed", "2142": "viral upper respiratory tract infections", "2143": "24 hpi was 1 mg/kg BW/ day", "2144": "35%", "2145": "more than 400", "2146": "contact with poultry or visited live animal markets", "2147": "some sporadic cases seemed to be a result of human to human transmissions", "2148": "acute respiratory disease", "2149": "three to five million", "2150": "250,000 to 500,000", "2151": "influenza virus infections are often accompanied by other viral pathogens", "2153": "66%", "2154": "other viral pathogens", "2155": "interference with viral attachment", "2156": "combining carrageenan with an NI therapy", "2157": "a high molecular weight sulfated polymer derived from red seaweed", "2158": "1.9 day faster", "2159": "decreased probability to develop complications", "2160": "significant reduction", "2163": "Synergistically Active", "2164": "significantly protects lethally influenza H1N1(09)pdm infected mice", "2165": "significantly protects lethally influenza H1N1(09)pdm infected mice", "2166": "significantly protects lethally influenza H1N1(09)pdm infected mice", "2179": "They have shown to differ in in-vitro susceptibility", "2180": "the combination therapies resulted in remarkably increased survival", "2182": "", "809": "macrophages and DC", "798": "pre-existing immune responses in the host", "800": "obstacle", "802": "heterologous antigens", "804": "heterologous antigens", "805": "their capability to induce robust T cell immune responses", "812": "Intracellular bacteria", "813": "harbours mutations in genes encoding proteins responsible for their survival in the animal host", "817": "Ad", "825": "Ad", "831": "modified vaccinia virus Ankara (MVA) and New York attenuated vaccinia virus NYVAC strains", "872": "Chickens (Gallus gallus) are a natural animal reservoir for Salmonella", "833": "their large DNA-packing capacity and their thermal and genetic stability", "836": "ease of production, safety profile, genetic stability", "838": "safety and efficacy", "841": "safety and efficacy", "845": "safety and efficacy", "858": "higher priming of naive T cells", "864": "This will theoretically reduce the exposure of the heterologous antigen to the immune system", "861": "This will theoretically reduce the exposure of the heterologous antigen to the immune system", "870": "higher priming of naive T cells", "874": "pre-existing immunity is a hindrance for subsequent induction of cell-mediated responses", "875": "induction of strong CTL immune responses", "876": "This will theoretically reduce the exposure of the heterologous antigen to the immune system", "877": "use of vectors derived from nonhuman sources, using human viruses of rare serotypes", "878": "repeated immunization with the same vaccine and dose", "879": "pre-existing immunity is a hindrance for subsequent induction of cell-mediated responses", "880": "masking the Ad vector inside dendritic cells", "601": "fecal\u2013oral contact", "602": "by raising the ratio of CD4 + /CD8 + T cells", "603": "intestine epithelial cells", "604": "intestinal mucosal immunity", "605": "physical, chemical, and biological barriers", "606": "nonpathogenic Gram-positive bacterium", "607": "maintenance of gut homeostasis", "608": "in the gut-associated lymphoid tissue", "609": "Peyer's patches (PPs), isolated lymphoid follicles (ILFs), mesenteric lymph nodes (MLNs), and scatter throughout the subepithelial lamina propria", "610": "lymphoid cells", "611": "serum IgG and mucosal SIgA", "612": "cytokines", "613": "one of the earliest pro-inflammatory cytokines", "1197": "12 December", "1199": "", "1201": "2003", "1202": "31 December", "1203": "26 January 2020", "1204": "2 weeks", "1205": "reverse transcription polymerase chain reaction tests", "1206": "1000 bed", "1207": "10 days", "1208": "rapid and transparent sharing of information between countries and agencies", "1209": "2012", "1210": "less than 2 weeks", "1211": "10%", "1212": "34%", "1213": "the volume and diversity of the information available and the relative lack of verification mechanisms", "1214": "autoinfection", "1215": "patients hospitalised", "1216": "", "1217": "a case infected significantly more contacts than the average", "1218": "up to 5 m people", "1939": "Between 3-5 million", "1940": "over 250 000", "1941": "53%", "1942": "ATII cells", "1944": "four", "1945": "A549 cells", "1946": "transmembrane domain", "1947": "CEACAM1-4L and CEACAM1-3L 21", "1948": "heterodimers", "1949": "signaling molecules", "1950": "Recognition of intracellular viral RNA by pattern recognition receptors", "1951": "Phosphorylation of CEACAM1 ITIM motifs and activation of caspase-3", "1952": "recognizing and killing infected cells", "1953": "modification of influenza hemagglutinin (HA) glycosylation", "641": "planning and conducting safe patient transport", "900": "two to three million", "901": "60%", "902": "Rotavirus", "903": "adenoviruses type 40 and 41", "904": "1907", "905": "1. Universal primer-PCR [41] ; 2. Random priming-based PCR [42] ; 3. Virus Discovery", "906": "detect novel variants of this viral family", "907": "guidelines that should be followed before an agent can be classified as a pathogen", "908": "the microbe occurs in no other disease as a fortuitous and nonpathogenic parasite", "909": "the microbe can induce the disease anew", "911": "the occurrence of the microbe in the disease can no longer be accidental", "912": "not applicable", "1721": "studies of protein\u2013protein interactions", "1722": "unique tolerance of genetic modifications", "1723": "high immunogenicity, relative antigenic simplicity and ability to activate a range of immune responses", "1724": "prophylactic and therapeutic agent", "1725": "bioconjugation", "1726": "large population sizes and fast generation times", "1727": "non-enveloped, rod-shaped viruses of Escherichia coli", "1728": "large population sizes, short generation times, small genome sizes and ease of manipulation", "1730": "", "1731": "bioengineering", "1732": "magnetics, optics, and electronics", "1733": "existing peptide-carrier technology", "1734": "the maximum tolerated size of the fused polypeptide, its copy number on the phage, and potentially, the structure of the displayed polypeptide", "1735": "fusion of polypeptides to two different capsid proteins", "1736": "tumor-targeting moieties", "1737": "a diverse pool of recombinant filamentous phage displaying an array of polypeptide variants", "1738": "do not use F-pili for entry", "1739": "using the phage as carrier to elicit antibodies against poorly immunogenic haptens or polypeptide", "1740": "high immunogenicity, relative antigenic simplicity and ability to activate a range of immune responses", "1741": "the maximum tolerated size of the fused polypeptide", "1742": "peptides incompletely or inadequately mimic epitopes on folded proteins", "1743": "anti-IgE antibody", "1744": "bovine serum albumin (BSA) and keyhole limpet hemocyanin", "1745": "bovine serum albumin (BSA) and keyhole limpet hemocyanin", "1747": "bacterial production and preparation heterogeneity", "1748": "bioconjugation", "1749": "immunogenic without adjuvant", "1750": "impaired the fertility", "1751": "MyD88 signaling", "1752": "through multiple mechanisms", "1753": "MyD88 signaling", "1754": "it is cleared from the blood within hours through the reticuloendothelial system", "1755": "speed, ease of purification and low cost of production", "1756": "preservation of biodiversity of other organisms in at-risk ecosystems", "1757": "M13 or fd phage", "1758": "M13 phage", "1759": "delayed tumor growth and improved survival", "1760": "the unanticipated ability of the phage to penetrate into brain tissue", "1761": "singlestranded DNA", "1762": "diversity of chemically addressable groups", "1763": "crossing of the blood-brain barrier and formation of highly ordered liquid crystalline phases", "1764": "crossing of the blood-brain barrier and formation of highly ordered liquid crystalline phases", "1765": "overlapping pVIII monomers", "1766": "crossing of the blood-brain barrier and formation of highly ordered liquid crystalline phases", "913": "a Gram positive, anaerobic bacterium", "914": "an adaptive strategy that enables bacteria to survive harsh environmental conditions for prolonged periods of time", "915": "Spo0A", "916": "major clostridial toxins A and B", "941": "Western blot", "933": "by mosquitoes", "934": "fatal encephalitis", "935": "35%", "936": "10%", "937": "TC83", "938": "differential gene expression of infected versus uninfected cells over time", "939": "endoplasmic reticulum (ER) stress", "940": "three classes of sensors", "942": "nuclear", "943": "early growth response 1", "1249": "the ability of a given host to tolerate an infection, and to return to a state of health", "1250": "respiratory", "1251": "respiratory", "1252": "2003", "1253": "8000", "1256": "35-50%", "1255": "10%", "1258": "double membrane vesicles", "1260": "severe lung pathology", "1262": "", "1263": "rapid progression to ARDS", "1265": "Disease resilience", "1266": "", "1267": "lack of both patient and experimental data", "1268": "not as widespread", "1269": "double membrane vesicles", "1270": "funding and research decreased", "1272": "the possibility that we will see a repeat of these types of outbreaks in the near future", "1271": "circumvent the immune response", "1273": "decrease mortality", "1274": "antiviral", "1275": "increased pathogen burden, and thus increase virus-induced pathology", "1276": "protect against inflammation-induced death", "1277": "", "1278": "ability of a host to tolerate the effects of an infection and return to a state of health", "1279": "obese, immunocompromised, diabetic or had cardiac disease", "1280": "higher neutrophil count and low T-cell counts", "1281": "rapid progression to ARDS", "1282": "If host gene responses are maintained this may increase disease resilience", "1283": "Clinical studies have started to correlate specific biomarkers", "325": "IAVs", "326": "identification of peptide ligands by receptors", "279": "Nod-like receptor family, pyrin domain-containing 3", "280": "lipopolysaccharide-primed macrophages", "281": "3a protein", "282": "transmembrane pore-forming viral proteins", "283": "Betacoronavirus", "284": "Coronaviridae", "285": "is an enveloped virus with a single-stranded positive-sense RNA genome", "287": "single-stranded", "288": "8,098", "289": "9.6%", "290": "interleukin 1 beta (IL-1\u03b2) and IL-18", "292": "by sensing the cellular damage or distress induced by viroporins", "293": "76", "294": "Ca 2+ -permeable", "296": "NLRP3 inflammasome", "887": "TNF-\u03b1", "888": "development of protective granulomas", "889": "MAPK phosphatase-1", "890": "Mycobacterium tuberculosis", "891": "one third", "892": "9.2 million", "893": "extracellular signal-regulated kinase 1 and 2 (ERK1/2), p38 MAPK, and c-Jun N-terminal kinase (JNK)", "894": "by phosphorylation", "895": "Elk1 and NFAT-AP-1", "896": "at least 10 MKPs", "897": "a cell wall component of Gram-negative bacteria", "898": "a Gram positive bacteria", "899": "MAPK", "1241": "Constant evolution of circulating influenza virus strains", "1242": "virus neutralizing monoclonal antibodies", "1243": "non-human strains", "1244": "protects against influenza virus challenge", "1245": "virus vectors enable native expression of influenza antigens", "1246": "preexisting immunity", "1247": "non-human strains", "1248": "whole virus inactivated, split virus inactivated, and subunit vaccines", "1254": "the virus is disrupted by a detergent", "1257": "intramuscularly", "1259": "three or four inactivated viruses", "1261": "by induction of humoral responses to the hemagglutinin (HA) protein", "1264": "hemagglutinin (HA) protein", "1472": "hemagglutination-inhibition (HI) assay", "1473": "strain-specific HI titer", "1474": "four-fold increase in titer post-vaccination, or a HI titer of \u22651:40", "1475": "serum antibodies", "1476": "serum antibodies", "1477": "as a nasal spray", "1478": "the same three or four influenza virus strains", "1480": "LAIV are temperature-sensitive and cold-adapted so they do not replicate effectively at core body temperature", "1481": "temperature-sensitive and cold-adapted", "1482": "in the mucosa of the nasopharynx", "1483": "induces serum antibody responses, mucosal antibody responses", "1484": "specific antibody responses to the HA, and to a lesser extent NA proteins for protection", "1485": "", "1486": "February", "1487": "safety in immunocompromised individuals still remains a concern", "1488": "antigenic match", "1489": "biannual reformulation of seasonal influenza vaccines", "1490": "diversity of the immune response", "1491": "improved understanding of immunity to conserved influenza virus antigens", "1492": "self-replicating nature of the RNA", "1493": "self-replicating nature of the RNA", "1494": "self-replicating nature of the RNA", "1495": "preexisting immunity remains a concern", "1496": "preexisting immunity", "1497": "53", "1498": "Recombinant live-attenuated or replication-deficient influenza viruses", "1501": "Adenovirus 5", "1503": "tested for gene delivery and anti-cancer agents, as well as for infectious disease vaccines", "1505": "their genome is very stable", "1506": "can evade anti-Ad5 immune responses while maintaining effective antigen delivery and immunogenicity", "1507": "their genome is very stable", "1508": "their genome is very stable", "1509": "enabling virus evasion from immunity", "1512": "robust mucosal immune responses and may bypass preexisting vector immunity", "1516": "preexisting immunity", "1524": "non-HA antigens, influenza nucleoprotein (NP) and matrix 2 (M2) protein", "1526": "The vaccine was well tolerated", "1530": "two clinical trial failures", "1531": "", "1535": "the vaccine did not achieve efficacy", "1540": "neutralizing antibody responses", "1543": "improve immunogenicity", "1544": "", "1579": "Autographa californica nuclear polyhedrosis virus", "1549": "potential for preexisting immunity", "1550": "", "1551": "", "1553": "virus-vectored vaccines", "1557": "Prime-boost strategies", "1559": "increased immunogenicity", "1560": "increased immunogenicity", "1561": "increased immunogenicity", "1562": "increased immunogenicity", "1563": "Many of these vectors have been extensively studied or used as vaccines against wild type forms of the virus", "1564": "positive-sense, single-stranded RNA viruses of the Togaviridae family", "1565": "Semliki Forest virus (SFV), Sindbis (SIN) virus, Venezuelan equine encephalitis (VEE) virus", "1566": "deliver passive immunity to influenza", "1567": "deliver passive immunity to influenza", "1568": "self-replicating nature of the RNA", "1569": "induce potent HA-specific immune response", "1570": "the VEE targets antigen-presenting cells in the lymphatic tissues, priming rapid and robust immune responses", "1571": "self-replicating nature of the RNA", "1572": "subcutaneous immunization", "1573": "the vaccine was immunogenic", "1574": "the vaccine was immunogenic", "1575": "adenoviruses", "1576": "enabling virus evasion from immunity", "1577": "enable native expression of influenza antigens", "1578": "may overcome the current limitations of influenza vaccines", "1580": "VSV-HA", "1581": "non-specific protection from subsequent influenza virus infection", "1582": "a single-stranded, negative-sense RNA virus that causes disease in poultry", "1583": "well-tolerated, even at high doses delivered intravenously", "1584": "well-tolerated", "1585": "well-tolerated", "1586": "well-tolerated", "1587": "cross-clade", "1588": "little or no preexisting immunity", "1589": "stable RNA genome and no DNA phase in virus replication cycle", "1590": "Mice intranasally vaccinated with a single dose of PIV5-H5 vaccine had robust serum and mucosal antibody responses", "1636": "use of poxviruses as vectors", "1637": "attenuated VSV vectors", "1638": "safe for use in children, adults, elderly, and immunocompromised persons", "1639": "very effective stimulators of both cellular and humoral immunity", "1640": "New York vaccinia virus", "1642": "chick embryo fibroblasts and Vero cells", "1643": "very attenuated and considered safe for use in humans of all ages", "1644": "cross-reactivity originally described with cowpox", "1645": "", "1646": "intramuscularly", "1647": "improved understanding of immunity to conserved influenza virus antigens has raised the possibility of a universal vaccine", "1648": "safety and immunogenicity", "1649": "improved understanding of immunity to conserved influenza virus antigens", "1650": "currently licensed influenza vaccines have not fully met these goals, nor those specific to inducing long-term, robust immunity", "1651": "annual vaccination", "1652": "virus neutralizing monoclonal antibodies that cross-react with many subtypes of influenza virus", "1653": "readily modified and to express transgenes", "1654": "induce immunity at sites of inductive immunity to natural infection", "1655": "virus vectors enable native expression of influenza antigens", "1656": "the intrinsic augmentation of immunity induced by the vector", "1175": "viruses and microorganisms", "1176": "Retroviruses", "1177": "ribozymes or viroids", "1178": "Rickettsia", "1179": "Ribozymes", "1180": "ribozymes", "1181": "Lipid vesicles", "1182": "The presence of the replicase enzyme was still necessary", "1183": "DNA synthesis depends on RNA synthesis", "1184": "circular single-stranded RNAs", "1185": "genetic triplet code", "1186": "structural information", "236": "older adults", "225": "Community spread", "226": "More than half", "227": "March 16", "230": "isolate at home during their illness", "231": "betacoronavirus", "232": "", "233": "Pandemics begin with an investigation phase, followed by recognition, initiation, and acceleration phases", "234": "acceleration phase", "237": "hospitalizations and deaths", "238": "rRT-PCR test", "235": "China", "228": "case identification, contact tracing, clinical management, and public communications", "244": "severe acute respiratory syndrome coronavirus 2", "245": "December 2019", "246": "Wuhan, China", "247": "daily air travel volume", "272": "", "239": "Noncontaminated CT disinfection", "240": "", "241": "diagnosing and categorizing", "242": "N95", "243": "1 mm-thick", "1238": "an extraordinary event which is determined to constitute a public health risk to other States through the international spread of disease and to potentially require a coordinated international response\"", "1239": "an extraordinary event which is determined to constitute a public health risk to other States through the international spread of disease and to potentially require a coordinated international response", "1240": "GISAID) platform", "1219": "December 2019", "1149": "pneumonia", "1151": "pharyngeal swab", "1160": "positively correlated", "1168": "", "1169": "positively correlated", "1171": "radiographic diagnosis with 5-day fever and 1-day continuous dry coughing", "1170": "positively correlated", "1172": "the digestive tract might be one extrapulmonary site for virus replication", "1173": "ACE2", "1174": "viral RNA outside of the respiratory tract", "2178": "8 August 2014", "2181": "Personal Protective Equipment", "2183": "sub-Saharan countries", "2184": "embodied experience, routine, and tacit knowledge", "2199": "spherical, enveloped, and the largest of positive-strand RNA viruses", "2200": "dromedary camels", "1187": "199", "1188": "2 to 4 February 2020", "1190": "14 days of quarantine", "1191": "a passenger who started coughing from 19 January 2020", "1192": "1 February", "1193": "199", "1194": "5.0 days", "1196": "greatly reduced the number of infections", "1189": "1373", "1235": "31 December 2019", "1236": "m = 63.1 million", "1237": "100q = 2.1%", "314": "Protease inhibitor", "315": "Rupintrivir was well tolerated and reduced viral loads and respiratory symptoms", "308": "viral aetiology", "309": "respiratory syncytial virus", "310": "human rhinovirus", "311": "human rhinovirus", "313": "chronic airway inflammation, and a history of respiratory symptoms", "317": "morbid obesity", "319": "two", "320": "haemagglutinin (HA) and the neuraminidase (NA)", "322": "amantadine", "323": "H275Y", "324": "difficulty with aerosol delivery, cost and potential harm to healthcare workers", "546": "hemorrhagic fever with renal syndrome", "547": "enveloped, negative-sense RNA", "548": "rodents", "549": "plasma viral load", "551": "antiviral medicine", "552": "CC", "554": "IFITM1, 2, and 3", "555": "inhibiting virus entry into the host cells", "556": "rs12252 C", "806": "lag between infections and deaths", "807": "11th March", "808": "", "796": "timings of school and university closures", "797": "semi-mechanistic Bayesian hierarchical model", "799": "reproductive number", "801": "Rt changing only when an intervention is introduced", "803": "each intervention has the same effect on the\nreproduction number across countries and over time", "810": "2-3 weeks", "811": "local and national Iockdowns", "814": "reduce COVID-19\nmortality and healthcare demand", "815": "", "819": "", "820": "23rd January", "823": "zero new confirmed indigenous cases in Wuhan by\nMarch 19th", "827": "", "829": "importation being the dominant source of new infections early\nin the epidemic, rather than local transmission", "837": "back-calculate infections from\nobserved deaths", "839": "5.9 [1.9-15.2] million", "840": "9.8%", "843": "15.0%", "844": "Germany\nand Norway", "847": "1.1%", "848": "3.7%", "849": "11.43%", "850": "", "851": "Country %", "852": "9.8%", "853": "0.97", "854": "", "855": "", "856": "11.43%", "857": "", "859": "", "862": "there is a 2-3-week period between\ninfection, onset of symptoms and outcome", "869": "The close spacing of interventions in time", "871": "mortality", "873": "fit a counterfactual model without the interventions\nand compare this to the actual model", "1071": "populations with all but essential internal travel banned", "1074": "underreporting", "1076": "Antibody responses", "1078": "isolation if travelling back from an epidemic country such as China", "1079": "banning all public events of more than 100 participants", "1080": "banning large gatherings and advising individuals not to socialize outside\ntheir households", "1081": "banning large gatherings and advising individuals not to socialize outside\ntheir households", "1083": "populations with all but essential internal travel banned", "1084": "time from infection to the onset\nof symptoms", "1085": "time from the onset of symptoms to death", "1086": "11.43%", "1095": "the initial reproduction number before interventions and the effect sizes from\ninterventions", "1097": "infection to onset of symptoms or infection-\nto-onset", "1098": "infection to onset of symptoms or infection-\nto-onset", "1102": "time from the onset of symptoms to death", "1100": "infection to onset of symptoms or infection-\nto-onset", "1103": "23.9 days", "1104": "discrete renewal process", "523": "10.8%", "525": "phase 6", "527": "meaning that the A/H1N1 flu had spread in more than two continents and reached pandemic proportions", "528": "$30-$100 billion", "881": "through respiratory tract and then induced pneumonia", "882": "respiratory, fecal-oral or body fluid routes", "883": "unreliable", "884": "unreliable", "885": "serology", "886": "negative detection from oral swabs", "1057": "50 million deaths worldwide", "1058": "5", "1059": ">2.5%", "1060": "50 million deaths worldwide", "1062": "highly conserved viruses with two receptor-binding variants", "1063": "", "1064": "early 1990s", "1065": "With the appearance of a new H2N2 pandemic\nstrain in 1957 (\u201cAsian \ufb02u\u201d), the direct H1N1 Viral descen-\ndants 0f the 1918 pandemic strain disappeared from human\ncirculation entirely", "1066": "1918", "1068": "", "1070": "None of these Viral descendants, however,\napproaches the pathogenicity", "1072": "substantially lower\nrates ofillness and death", "1073": "descendants of the 1918\nVirus still persists enzootically in pigs", "1075": "its origin remains puzzling", "1082": "European military camps", "1087": "the 1918 Virus appears to be an avianlike in\ufb02uenza\nVirus derived in toto from an unknown source", "1088": "death rates were 5 7 20 times\nhigher than expected", "1089": "spring", "1090": "1918", "1091": "March 1918", "1092": "50 million deaths worldwide", "1093": "fall\nand winter of 191871919", "1094": "exceptional pathogenicity", "1096": "newly shifted\nin\ufb02uenza Viruses behave differently when they \ufb01nd a uni-\nversal or highly susceptible human population", "1099": "lower environ-\nmental temperatures and human nasal temperatures", "1101": "cannot", "1105": "H1N1 Viruses and reassorted\nH2N2 and H3N2 Viruses", "1106": "identical or closely related Viral", "1107": "not a reassortant Virus produced from old\nexisting strains that acquired 1 or more new genes", "1108": "avian Viruses likely\nundergo little antigenic change", "1109": "young", "1110": ">2.5%", "1111": "<65 years of age", "1112": "25%", "1113": "the 1918 Virus had an intrinsically high Virulence", "1114": "the 1918\npandemic was different in degree, but not in kind, from\nprevious and subsequent pandemics", "1117": "antiin\ufb02uenza drugs", "1120": "", "1123": "Viral sequence data now suggest that the entire 1918\nVirus was novel to humans in, or shortly before, 1918", "1872": "exponential growth pattern", "1875": "469 (95% CI: 403-540) unreported", "1877": "basic reproduction number", "1879": "21-fold", "1880": "2.56", "1881": "between 1 and 15 January 2020", "1882": "Wuhan, China", "1884": "fever, cough, and shortness of breath", "1886": "41", "1889": "2066", "1891": "", "1892": "", "1893": "Wuhan Municipal Health Commission", "1894": "National Health Commission of China", "1895": "exponential growth", "1907": "exponential growth", "529": "gisaid.org", "531": "E and RdRp", "266": "smoking is most likely associated with the negative progression and adverse outcomes", "267": "smokers are twice more likely than non-smokers", "2185": "information is rapidly evolving", "2186": "", "2187": "January 30, 2020", "2188": "January 24, 2020", "2189": "Chicago", "2190": "January 30, 2020", "2191": "", "2192": "January 31, 2020", "2193": "", "2194": "", "2195": "Healthcare personnel", "2196": "", "2197": "", "2198": "challenging", "1909": "Over 168 million", "1910": "those in complex humanitarian crises", "1911": "Poor governance, public distrust, and political violence", "1912": "Populations affected by humanitarian crises", "1913": "latrines in crisis settings are often shared and distant from residential shelters, conferring a high risk of gender-based violence", "1914": "reduce access to limited healthcare", "1915": "limited public health, laboratory, and primary care services", "1916": "delivering accurate and actionable information to potentially affected populations", "1917": "Frequent displacement and limited contact information", "1918": "overcrowding", "1919": "humanitarian crises", "1920": "to protect healthcare workers", "1921": "WASH", "1922": "", "1923": "distribution of soap to households in humanitarian settings", "1924": "rights to dignity", "1925": "Widespread introduction of alcohol-based hand rubs", "1926": "The Sphere Handbook", "1927": "", "1928": "prevention of illnesses transmitted by the faecal-oral route", "1929": "latrines in crisis settings are often shared and distant from residential shelters", "1930": "accessing latrine-adjacent handwashing stations", "1931": "Crisis-affected community engagement", "1932": "mitigation plans will fall short of health and human rights obligations in outbreak response", "1933": "Transparent and credible information-sharing mechanisms", "1934": "Diplomacy bridging long-standing mistrust of public health and biomedical interventions and facilitating engagement with contentious actors", "259": "20 million", "286": "Many families were too poor to buy food and coal, and to afford health care expenses when their family members were ill", "291": "almost had nothing in their hands to help individuals who were infected by influenza viruses", "295": "anti-influenza virus drugs", "297": "10.2/100,000", "299": "We do not have a universal vaccine to prevent all influenza virus infections", "300": "0.005%", "301": "communication and information exchange", "302": "new effective anti-viral agents and vaccines", "303": "32.14%", "304": "Only those who have very severe flu-like symptoms would see doctors"}